



# Understanding a Patient's Daily Experience Through Mobile Devices and Wearables

## The MIPACT Study




**Nicole Eyrich, MPH**

**Jessica Golbus, MD, MS**

**Sachin Kheterpal, MD, MBA**





# Disclosures

- The presenters' institution (University of Michigan) receives sponsored funding from PCORI, NIH, Apple, Blue Cross Blue Shield of Michigan, American Heart Association, Merck, and Becton Dickinson
- Sachin Kheterpal and other MIPACT co-investigators have held or may hold publicly traded Apple stock.
- No personal financial, consulting, or other relevant equity relationships

# Overview

**01** MIPACT Overview & Protocol Design

**02** In-person vs all-remote Enrollment

**03** Preliminary Inferences

**04** The VALENTINE Study

**05** THRIVE

01


# Overview & Protocol Design



# The MIPACT Study

- Goal: Understand how modern person-centered data may inform understanding of health, wellness, and disease trajectories.
- This study combines Apple Watch sensor data with blood pressure monitoring, survey data, health records, and genetic information.
- Sponsors: Apple, UM

# The MIPACT Study Design



# MIPACT



16 months



6,765

# Remote MIPACT



10 months



925

02

# Recruitment and Enrollment





# Recruitment and Enrollment Overview

## Most recruitment tasks completed virtually

- Phone calls
- Emails
- Social media advertisement
- Postal mail

Enrollment visits were conducted via videoconferencing and screen-sharing software. Participants were required to have a secondary device (tablet, laptop, desktop, etc.), other than their iPhone, for the video visit.

### Visit 1

- Informed consent
- Assessment of protocol understanding
- Download required study apps

Ship devices to participant



~2 weeks later



### Visit 2

- Device configuration
- Practice study tasks
- Place lab orders

## Recruitment

### Study Population



123,448 patients approached\*



5,238 phone calls

131,609 emails

4 social media outlets



11 community events

3,237 patients approached

25,695 postcards



6,765 participants enrolled




Participants are placed into groups based on clinical and demographic factors.

# Informed Consent and Data Collection

Nearly all study activities are conducted through a mobile application, MyDataHelps.

- Informed Consent (no paper)
- Guided study tasks
- Surveys
- Mobile health data collection (step count, blood pressure, heart rate, etc.)
- Compliance reminders
- EHR data integration



← Back Step 6 of 9 Cancel

Take your blood pressure  
now



Press **Start/Stop**  
**once** on your cuff

Don't move around or speak.

- Your cuff will inflate and measure your blood pressure.
- When you see the measurements on the monitor, press **Next**.
- If you see an **error** on the monitor, redo the measurement.

Next: Sit still and relax

# Comparing Methodologies

	<b>In-Person</b>	<b>Virtual</b>
<b>Enrolled Participants</b>	6,765	925
<b>Withdrawal/Protocol Failure Rate</b>	7%	3.5%
<b>Basic Completion Reached in Phase 1</b>	98%	98%
<b>Basic Completion Reached in 80% of Phase 2 Months</b>	50%	50%
<b>Rescheduled Appointments</b>	6%	11%
<b>Cancelled or No-show Appointments</b>	8%	8%

03

# Preliminary inferences



# Focus on diverse enrollment yields results



## Age

18-40 2,265 (35%)

41-64 3,036 (47%)

65+ 1,153 (18%)

## Race

White 3,657 (57%)

Asian 1,094 (17%)

Black 1,090 (17%)

Other 615 (9%)

## Ethnicity

Hispanic 737 (11%)

Non-Hispanic 5,717 (89%)

## Clinical diagnoses

Diabetes 666 (10%)


Depression 1734 (27%)

Hypertension 2105 (33%)

# Compliance high despite study burden



Compliance over Time by Quarter



- Percent of Months Meeting Basic Completion in the Quarter
- Percent of Months Meeting Comprehensive Completion in the Quarter

# Data availability

Wearable data  
across age,  
Michigan P  
(MIPACT) st  
observation

Jessica R Golbus\*, Nicole A

Summary  
Background Wearable  
device data for diverse  
rate, step count, and h

The screenshot shows a web browser window with the URL [researchtools.mipactstudy.org](https://researchtools.mipactstudy.org). The page title is "Cohort Identification Toolkit". The MIPACT logo is in the top left. The main text reads: "This app contains physiologic and activity data for nearly 7,000 MIPACT study participants from the University of Michigan. To protect patient anonymity, data will only be displayed when 10 or more study participants have the selected combination of attributes. Data is available from the first 90-days of study participation and may be updated at a later date. Visit our [MIPACT](#) study website for more information."

Below the text is a section titled "Read Instructions First" with a list of six instructions:

1. To build your cohort of interest, adjust the filters as needed.
2. Selecting more than one condition within a single box will provide you with normative data from participants with **either** condition.
3. If you choose to use a second or third "condition" box, you will be provided with normative data from participants that have **all** of the selected conditions.
4. Group 1 represents all MIPACT participants included in this dataset and will remain at the top of the results table.
5. Groups can be compared by clicking . Hovering over in the Group column provides you with the selected characteristics for that group.
6. Click to download a csv file of the summary health and activity data for your cohorts.

The "Select Filters" section contains several filter boxes:

- Gender:
- Age:
- Race:
- Ethnicity:
- BMI:
- Beta Blocker:

At the bottom, there are three "Condition" input fields separated by "AND" labels.



<https://researchtools.mipactstudy.org>

# Power analysis assumptions using real data

Select Filters

Gender:

Age:

Race:

Ethnicity:



BMI:

Beta Blocker:

Condition:



View Results

Group	Heart Rate (All) (beats / min)	Resting Heart Rate (beats / min)	Systolic Blood Pressure (mmHG)	Diastolic Blood Pressure (mmHG)	Step Count	Exercise Minutes
#1 ⓘ Total 6454	Mean: 81 Median: 81 Std: 9 IQR: 12	Mean: 64 Median: 64 Std: 8 IQR: 11	Mean: 122 Median: 121 Std: 10 IQR: 14	Mean: 77 Median: 76 Std: 8 IQR: 10	Mean: 7511 Median: 7202 Std: 2805 IQR: 3436	Mean: 29 Median: 24 Std: 20 IQR: 21
#2 ⓘ Total 83	Mean: 75 Median: 73 Std: 9 IQR: 11	Mean: 61 Median: 61 Std: 7 IQR: 7	Mean: 131 Median: 130 Std: 10 IQR: 11	Mean: 78 Median: 77 Std: 6 IQR: 6	Mean: 6206 Median: 5797 Std: 2677 IQR: 3274	Mean: 24 Median: 20 Std: 17 IQR: 17



 



# Mood and stress changes during the pandemic



# Activity changes during the pandemic



# Key Takeaways


1. Large scale completely digital recruitment and enrollment is feasible
2. Protocol compliance comparable across both designs
3. Historical biases regarding digital tools may be inaccurate
4. Prospective trials should be powered using real data
5. Impact of COVID 19 pandemic on participants controversial

04

# The VALENTINE Study

**VALENTINE**  
Cardiac Rehabilitation Study

# The VALENTINE Study Design



## Telehealth Intervention

- Smartphone application with behavior tracking capabilities.
- Micro-randomized notifications focused on activity and goal-setting.
- Weekly emails to patients and exercise physiologists with a summary of past week's activity

## Primary (bold) and Secondary Study Measures

Domain	Measurement
Functional assessments	<b>Distance on 6-minute walk distance (primary)</b>
	Average step count (secondary)
	Minutes in target heart rate zone
Quality of Life	SF-12, EQ-5D-5L
	PHQ-8
Process measures	System usability scale
Disease-specific questionnaires	Kansas City Cardiomyopathy Questionnaire, Seattle Angina Questionnaire
Safety endpoints	All-cause and cardiovascular hospitalization
	All-cause and cardiovascular death

# Just-In-Time Adaptive Intervention

## Activity Notifications:

- Promote low-level physical activity appropriate for current environment.
- Tailored on weather, time of day, day of week, phase of cardiac rehabilitation.

## Exercise Notifications:

- Encourage participants to plan their exercise and suggest new activities.
- Tailored on season, phase of cardiac rehabilitation.



# The VALENTINE Population

	N	Mean (SD or %)
<b>Age, years</b>	211	59.7 (10.6)
<b>Sex</b>		
<i>Female</i>	66	31%
<i>Male</i>	145	69%
<b>Race</b>		
<i>Asian</i>	7	3%
<i>Black</i>	12	6%
<i>White</i>	178	84%
<b>Phone type</b>		
<i>iPhone (Apple Watch)</i>	132	63%
<i>Android phone (Fitbit Versa 2)</i>	79	37%
<b>Indication for cardiac rehabilitation</b>		
<i>s/p PCI or CABG</i>	136	64%
<i>Valve repair or replacement</i>	48	23%
<i>Valve repair/replacement + PCI/CABG</i>	6	3%
<i>CAD or ACS, not revascularized</i>	21	10%


# VALENTINE Study: Baseline Data

	N	Mean (SD)
<b>Select Functional Endpoints</b>		
6-minute walk distance, meters (remote)	202	493 (141)
Average daily step count (watch)*	206	6831 (3377)
<b>Select Quality of Life Endpoints</b>		
KCCQ, overall summary score	80	80.2 (16.1)
SAQ, physical limitation scale	157	87.2 (17.0)
SAQ, quality of life scale	166	75.1 (20.9)
EQ-5D VAS (0-100)	210	72.8 (18.1)

\* Baseline step count based on compliant days during the first week of study, defined by 8 or more hours of watch wear.



# Lessons Learned



## Data Management

- ❖ **Active data management is essential:** Automated texts and an eDashboard.
- ❖ **Participants must use app to ensure data syncs.**

## Digital Endpoints

- ❖ **6-minute walk test:** Clinically accepted though frequent technical challenges.
- ❖ **Step count:** Easy to collect though compliance is essential.
- ❖ **Surveys:** Easy to complete, high adherence

05


THRIVE

The logo for THRIVE features the word "THRIVE" in a black, serif font. A green plant sprout with three leaves is positioned between the "R" and "I", partially overlapping the "R" and "I".

**Trajectories of Recovery after  
Intravenous propofol versus inhaled  
Volatile anesthesia**

# Recovery after surgery is not linear

- One patient back to baseline in 2 days
- Another patient takes more than a week



# General anesthesia is ubiquitous

Henry Bigelow reports surgical anesthesia with Ether, an inhaled volatile anesthetic

1846




1977

John Glen discovers Propofol, an intravenous anesthetic

300 million surgical patients yearly worldwide

2021



80% inhaled volatile vs. 20% propofol

## Propofol TIVA Advantages

Decreased postoperative  
nausea and vomiting

Fewer side effects



## Gaps in our Knowledge

Awareness risk

Cognitive recovery

Sense of well-being

Postoperative pain

Ability to communicate

Return to usual activities

Sleep and restfulness

Enjoyment of food

## Inhaled Volatile Advantages

Predictable dose-response  
relationship

Technical ease of  
administration




# THRIVE: Trajectories of Recovery after Intravenous propofol vs inhaled Volatile anesthesia

- Multicenter, pragmatic randomized control trial to evaluate superiority of propofol TIVA over inhaled volatile general anesthesia for patient experience and outcomes
- Support from the Patient-Centered Outcomes Research Institute (PCORI). \$29.6 M total over 6.5 years
- 12 MPOG enrollment centers, 12,500 patients
- Led by UMichigan, Wash U, UPenn, Stanford

# Multicenter Perioperative Outcomes Group



- 17 Million perioperative patient records extracted, mapped, de-identified, and available for research and performance improvement
  - Every medication administration and outpatient prescription
  - Every physiologic, every 60 seconds
  - Laboratory values 365 days pre/post
  - Discharge ICD9/10
  - Readmissions, long term costs, patient reported outcomes for a subset
- 26 health systems, 60+ hospitals, 22 states, 2 countries, 6 EHR vendors
  - 35 BILLION vital signs for these patients...this is BIG data
- > 5500 providers receiving monthly email feedback across 40 performance measures







**M** | MICHIGAN MEDICINE  
UNIVERSITY OF MICHIGAN



# THRIVE candidate centers




# Study overview



\* Wearable devices acquired from independent funds


# Data Sources and Systems




# Mobile Health & Wearables

MyDataHelps implemented via iPhone, Android, tablet, and responsive web

- Informed Consent
- PROs
- Bring your own device wearables (BYOD)
- Compliance reminders
- Return of results
- Independently funded wearables for subset of participants



# Why mobile devices & wearables?



- Recovery assessment at pre-specified timepoints belies dynamic reality
- Significant PRO burden already (Day 0, 1, 2, 7)
- Patient "expectations" of recovery may bias reporting
- Objective (yet exploratory) data from wearables



Sleep Duration



Sleep Quality



Step Count




Exercise Minutes




Stand Hours

# PROSPER pilot study – steps per day



Perioperative Movement | **Average Steps** | Perioperative Energy Expenditure | Perioperative Weight | Perioperative Heart Rate | Data Missingness

# There is hope...



# Key Takeaways

1. Mobile health tools are viable across diverse populations
2. In person and remote enrollment scalable despite technical complexity
3. Wearable data research can use valid power analyses
4. Integration of pragmatic trials techniques, EHR data, smartphones, and wearables reflects comprehensive patient experience



# Thank you to the MIPACT, MPOG, and THRIVE team



**Meredith Bailey, MSN, RN**  
OI COORDINATOR



**Genevieve Bell**  
DEVELOPER



**Kathryn Buehler, MS, RN**  
CLINICAL PROGRAM  
MANAGER



**Michael Burns, MD, PhD**  
FACULTY



**Sachin Kheterpal, MD, MBA**  
EXECUTIVE DIRECTOR



**Tory Laca, MBA**  
ADMINISTRATIVE  
PROGRAM MANAGER



**Tiffany Malenfant, MSN, RN-  
BC**  
CLINICAL INFORMATICS  
SPECIALIST



**Mike Mathis, MD**  
RESEARCH DIRECTOR



**David Clark**  
ADMINISTRATIVE  
SPECIALIST



**Robert Coleman**  
PROGRAMMER



**Douglas Colquhoun, MB ChB,  
MSc, MPH**  
RESEARCH FACULTY



**Mark Dehring**  
TECHNICAL TEAM  
MANAGER



**Ronnie Riggat**  
ADMINISTRATIVE  
ASSISTANT




**Michelle Romanowski**  
DEVELOPER



**Sandy B. Rozek, MA**  
RESEARCH  
FACILITATOR



**Nirav Shah, MD**  
QUALITY IMPROVEMENT  
DIRECTOR



**Chris Heiden**  
TECHNICAL SUPPORT  
LEAD



**Rachel Hurwitz**  
RESEARCH ASSISTANT



**Allison Janda, MD**  
RESEARCH FELLOW  
CARDIAC OI  
SUBCOMMITTEE LEAD



**Jay Jeong, MSI**  
DEVELOPER



**Anik Sinha**  
DEVELOPER




**John Vandervest, MS**  
DATA SCIENTIST



**Shelley Vaughn, MPH**  
LEAD RESEARCH  
FACILITATOR



**Andrew Zittleman, MSN, RN**  
CLINICAL INFORMATICS  
SPECIALIST



# MIPACT study team – pre-COVID

